
Doubling Survival in Pancreatic Cancer, Rethinking Obesity, and The Return of Maggot Therapy
This week, Dr. Joe looks at how new science is reshaping everything from one of the deadliest cancers to how we talk about weight—and even what we’re willing to use to heal a wound. A phase III trial of a new oral pill for metastatic pancreatic cancer has been called a “grand slam,” with patients on the drug living about 13 months on average compared with 6 months on standard chemotherapy. Dr. Joe explains how targeting a common RAS gene pathway can double survival while preserving quality of life, and why genetic markers are becoming as important as where a cancer…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.